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The complement system plays a key role in several dermatological diseases. Overactiva-
tion, deficiency, or abnormality of the control proteins are often related to a skin disease.
Autoimmune mechanisms with autoantibodies and a cytotoxic effect of the complement
membrane attack complex on epidermal or vascular cells can cause direct tissue damage
and inflammation, e.g., in systemic lupus erythematosus (SLE), phospholipid antibody syn-
drome, and bullous skin diseases like pemphigoid. By evading complement attack, some
microbes like Borrelia spirochetes and staphylococci can persist in the skin and cause pro-
longed symptoms. In this review, we present the most important skin diseases connected
to abnormalities in the function of the complement system. Drugs having an effect on
the complement system are also briefly described. On one hand, drugs with free hydroxyl
on amino groups (e.g., hydralazine, procainamide) could interact with C4A, C4B, or C3 and
cause an SLE-like disease. On the other hand, progress in studies on complement has led to
novel anti-complement drugs (recombinant C1-inhibitor and anti-C5 antibody, eculizumab)
that could alleviate symptoms in diseases associated with excessive complement activa-
tion.The main theme of the manuscript is to show how relevant the complement system is
as an immune effector system in contributing to tissue injury and inflammation in a broad
range of skin disorders.
Keywords: hereditary and acquired angioedema, systemic lupus erythematosus, vasculitic syndromes, pemphigus,
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INTRODUCTION
The complement system refers to a group of up to 50 molecules
that play a role in various clearance processes and in host defense
against microorganisms. Most of these complement components
are in blood plasma but some act on cell membranes as receptors
for activated components or as regulators that protect host tissues.
There are three separate activation routes: the classical, alterna-
tive, and lectin pathways. All pathways lead to activation of C3,
and continue to the formation of biologically active factors such
as C5a, and to the lysis of cells and microbes by the membrane
attack complex (MAC). While MAC primarily destroys Gram-
negative bacteria, components C1q,C4b,C3b,and iC3b participate
in the opsonophagocytic clearance of microbes and endogenous
waste products. Activation of the complement system plays an
important role in skin defense against microbial infection but also
mediates inflammation and tissue injury. A simplified scheme of
the complement system is shown in Figure 1.
Skin as a whole is a large organ. It takes part in a spec-
trum of immunological reactions and is a sensitive indicator of
immune dysregulation. Recent studies indicate that skin can have
“memory,” i.e., recent immunological reactions can leave a local
population of effector or regulatory T cells to activate or down-
regulate immune reactions, respectively (1). The skin microbiome
together with antimicrobial peptides plays a role in immunity.
On the other hand, skin reflects several internal injuries of the
body and mirrors changes in the immune status of the indi-
vidual. Keratinocytes of the epidermis of human skin produce
several cytokines, chemokines, and many complement proteins.
Locally synthesized complement components are believed to play
an important role in host defense and inflammation at the organ
level. The synthesis of certain complement proteins by human
skin keratinocytes and fibroblasts can be either upregulated or
downregulated.
Human keratinocytes have been reported to produce the com-
plement inhibitors factor H (FH) and factor H-like protein-
1 (FHL-1) as well as the C3b inactivator enzyme factor I for
which FH and FHL-1 act as cofactors. The production of these
factors is upregulated by interferon-γ (IFN-γ) (2, 3). Recently,
Riihilä et al. (4) have presented results indicative of upregula-
tion of FH and FHL-1 in cutaneous squamous cell carcinoma
(cSCC) cell lines and in cSCC tumors, also to a lesser extent in
cSCC in situ. The expression of FH by cSCC cells was upregu-
lated by IFN-γ. Timar et al. (5) have further demonstrated that
human keratinocytes produce the terminal complement compo-
nents C5, C7, C8γ, and C9, but release only C7 and C9. Of the
cytokines, tumor necrosis factor alpha (TNF-α) strongly upreg-
ulated C9 production. Also C3 (6), factor B (7), complement
receptors CR1 and CR2 (8), cC1qR (9), and C5aR (10), and the
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FIGURE 1 | A schematic figure of the complement system. The figure
shows the three complement activation pathways (yellow boxes), the
components needed for activation (in black, like C3), the targets that activate
complement (green), the different complement regulators (blue), and
consequences of deficiencies of individual complement components leading
either to infections (lilac boxes) or to complement deficiency syndromes (in
red boxes). Explanations of the different arrow types are shown in the key box
(bottom right). The classical pathway (top left) can be activated by C1q that
binds to immune complexes or C-reactive protein. The lectin pathway (bottom
left) becomes activated by mannan-binding lectin (MBL) or ficolins that bind to
carbohydrates or acetylated moieties. The alternative pathway (top right)
becomes activated spontaneously upon interaction with a foreign surface
(e.g., microbes) that lacks complement inhibitors. After binding of C1q, MBL,
or ficolins to their targets, the serine esterases attached to them (C1r, C1s,
MASPs) become activated and cleave the subsequent components C4 and
C2. C4b and C2a together generate the classical pathway C3/C5 convertase.
Activation of C3 is central to complement activation. It can become activated
by the alternative pathway C3/C5 convertase C3bBb composed of C3b and
the activated factor B. Factor D activates factor B and properdin (P) stabilizes
the C3bBb enzyme. Because of involvement of C3b in C3 cleavage, a positive
feedback is created and the alternative pathway can amplify complement
activation regardless of the initial activation route. C3 activation products, C3b
and iC3b are important opsonins recognized by the phagocyte C3b (CR1) and
iC3b (CR3) receptors. After activation of C5, the five terminal plasma
glycoproteins (C5b, C6, C7, C8, and C9) bind sequentially to each other to
generate the cytolytic membrane attack complex (MAC). Regulation of
complement activation occurs at all key steps of the cascade. C1r and C1s are
inhibited by the plasma protein C1-inhibitor (C1-INH). C1-INH also inhibits
analogous MBL-associated serine protease, MASP-2. Activity of the classical
pathway C3/C5 convertase, C4b2a, is inhibited by the plasma factor
C4b-binding protein (C4bp). The activity of the alternative pathway C3/C5
convertase, C3bBb, is inhibited by the regulators factor H, DAF, and MCP. On
human cell membranes, the main inhibitor of MAC is CD59. Because of the
importance of complement as defense and inflammatory mediator system,
its deficiencies can predispose to serious diseases. The deficiency in the
clearance part (classical pathway) can predispose to SLE, whereas the
alternative and terminal pathway deficiencies predispose to microbial
infections. Deficiencies of complement regulators predispose to autoreactive
disorders, where complement is either excessively activated (HAE, DDD) or
misdirected against self cell surfaces (C3GN, aHUS, PNH). Leukocyte
adhesion deficiency is a rare consequence of CR3 defect. Abbreviations: SLE,
systemic lupus erythematosus; HAE, hereditary angioedema; C1-INH,
C1-inhibitor; PNH, paroxysmal nocturnal hemoglobinuria; DDD, dense deposit
disease; C3GN, C3 glomerulopathy; aHUS, hemolytic uremic syndrome; LAD,
leukocyte adhesion deficiency; DAF, decay-accelerating factor; MASP,
mannose-binding lectin-associated serine protease; CR, complement
receptor; H, factor H; D, factor D; P, properdin; I, factor I; B, factor B; CD59,
protectin; MCP, membrane cofactor protein.
cell surface complement regulatory proteins membrane cofac-
tor protein (MCP/CD46), decay-accelerating factor (DAF/CD55),
and protectin (CD59) (11) have been found to be produced by
human keratinocytes. By producing complement factors needed
for activation, the skin could augment local complement attack
against invading microbes. Most complement components would,
however, come from blood plasma, but they get diluted in local
areas. Locally produced complement components can compen-
sate for dilution and add extra strength for complement acti-
vation, e.g., in areas of local infection. Importantly, not all
complement components are needed for opsonophagocytosis of
local microbes.
In human skin fibroblasts, TNF-α increases the synthesis of
factor B and C3, the activator proteins of the alternative path-
way (AP). IL-4, on the contrary, decreases the effect of TNF-α on
the synthesis of factor B (12). Synthesis of factor B and C3 are
also enhanced by LPS and IFN-γ (13). It has been demontrated
that fibroblasts also produce C1q (14) and FH (13), although the
main site of the synthesis of FH is the liver. Additionally, comple-
ment components C5–C9 have been presented to be produced by
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fibroblasts (15). Notably, C1q is not produced by the liver (16, 17).
Thus, its production is dependent on local synthesis. Macrophages,
dendritic cells, and other leukocytes produce C1q. The same holds
true for C7, whose synthesis does not take place in the liver (18).
Various types of dendritic cells, such as Langerhans cells carry
receptors for C1q, C3b, iC3b, and C3d to pick up antigens bound
to these factors. Depending on the nature of the antigen, type of
opsonin, and phagocytosing cell, the antigens can be processed in
different manners.
Decay-accelerating factor regulates autologous complement
activation by promoting dissociation of the alternative and clas-
sical pathway C3 and C5-convertases on cell surfaces. Peculiarly,
DAF is attached to elastic fibers in the extracellular matrix of the
dermis (19) and on epidermal cells (20). On cell membranes, DAF
expression is usually relatively low compared to other membrane
regulators (MCP and CD59), but its level can be readily upregu-
lated. Vitronectin, which prevents the membrane insertion of the
MAC, has also been found to associate with elastic fibers in the
dermis (21). The significance of these filament or fiber-associated
complement regulators is not clear. In some locations, DAF has
been shown to act as a receptor for microbes, like for P-fimbriated
E. coli in the urinary tract. Overall, however, the membrane and
soluble inhibitors protect host cells and suppress excessive inflam-
mation, while allowing house-keeping clearance functions and an
attack against invading microbes.
In the following text, we will present the most important skin
diseases linked to abnormalities in the activity or regulation of the
complement system. In addition to the diseases mentioned here,
complement plays a role in dermatological inflammatory diseases
such as in immediate phototoxic reactions, pustular dermatoses,
and in psoriasis as well as in fungal infections (22). Naturally, sev-
eral other immunopathogenetic mechanisms and signaling events
are involved in these diseases, but these pathways will not be dis-
cussed here. Because of the inflammatory and cytotoxic effects of
complement, it is important and now increasingly possible to con-
trol its functions. Therefore, drugs affecting complement activity
are also briefly presented.
HEREDITARY AND ACQUIRED ANGIOEDEMA
Hereditary angioedema (HAE) is caused by low levels or dis-
turbed functional activity of the complement control protein
C1-inhibitor (C1-INH), which is a serine protease inhibitor (ser-
pin) in plasma, also known as SERPING1 (23). C1-INH controls
the activities of C1r, C1s, and mannose-binding lectin-associated
serine proteases (MASP-1, -2, and -3) of the lectin pathway, factor
XII and kallikrein in the contact system, factor XI and thrombin
in the coagulation system, and tissue plasminogen activator (tPA)
and plasmin in the fibrinolytic system (24). Low levels of C1-INH
lead to increased tendency for cleavage of C4 and C2, and patients
often have low levels of these proteins. However, levels of C3 are
usually not affected.
C1-INH deficiency can be genetic or acquired. Functional C1-
INH levels in HAE patients are below 50% of normal. Two main
genetic types of C1-INH deficiency are known: in type I HAE
(85% of cases), low plasma levels of C1-INH occur, and in type
II HAE (15% of cases) C1-INH protein levels are normal but C1-
INH is dysfunctional. The latter is due to point mutations in the
FIGURE 2 |Typical features of four distinct complement-related
diseases with dermatological symptoms. (A) Hereditary
angioedema, (B) SLE, (C) urticarial vasculitis, and (D) bullous
pemphigoid. (A,C,D) are from the photogallery of the Clinic of
Dermatology and Allergology, Helsinki University Central Hospital and
(B) is from http://www.fightinglupus.org/sle-lupus.html
C1-INH gene. Additionally, a clinical syndrome resembling HAE
and termed as type III HAE has been described (25). It affects pre-
dominantly women. C1-INH function and its levels are normal.
One third of the patients have been found to have a mutation in
the clotting factor XII gene. For the rest of the patients, the under-
lying causes are unknown. One possibility is a defect in proteins
that are involved in bradykinin degradation (26–28).
Acquired angioedema (AAE) is characterized by activation of
the classical complement pathway and accelerated catabolism of
C1-INH. Two different forms of AAE have been described: type I,
which is associated with a B cell lymphoproliferative diseases and
type II, which is caused by autoantibodies to the C1-INH molecule
in otherwise healthy people (29, 30).
The clinical manifestations of angioedema are due to increased
levels of bradykinin as a consequence of uncontrolled cleavage of
kininogen by the plasma enzyme kallikrein (28). HAE is character-
ized by an increased vascular permeability in the deeper layers of
the skin and/or the gastrointestinal and laryngeal mucosa repre-
senting as angioedema. In addition to mucosal surfaces, attacks of
swelling are common at face or at limbs (Figure 2A). The swelling
usually lasts 3–4 days. Attacks can be precipitated, e.g., by surgical
procedures or stress. They do not respond to therapy by sym-
patomimetics, antihistamines, or steroids but can be controlled
therapeutically by plasma-purified or recombinant C1-INH or by
the bradykinin receptor antagonist icatibant. Also, tranexamic acid
has been used for the therapy or prevention of HAE attacks. Atten-
uated androgens, like danazol have been used for prophylaxis, but
are nowadays no longer a preferred option.
SYSTEMIC LUPUS ERYTHEMATOSUS
Among the strongest, known genetic risk factors for the devel-
opment of systemic lupus erythematosus (SLE) are deficiencies
of the classical complement pathway components (C1q, C1r, C1s,
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C4, or C2). Of the two C4 isoforms, C4A and C4B, particularly the
deficiency of C4A (a “null” allele) is associated with SLE (31).
Individuals with complete deficiency of C1q have the highest
prevalence of SLE. They usually also develop renal dysfunction
as a consequence of the disease (32). Animal studies have indi-
cated that 25% of mice with homozygous C1q deficiency also
develop end-stage renal disease (33). It is likely that complement
deficiency-related SLE represents one subtype of SLE. The role of
the classical pathway in clearing immune complexes has led to the
speculation that classical pathway deficiency leads to the devel-
opment of SLE because of an inability to clear antigen–antibody
complexes, chromatin, or other immune aggregates, resulting in
their tissue deposition. This process may trigger an inflamma-
tory response and the exposure of autoantigens, with subsequent
development of autoimmunity (34). It is possible that, for exam-
ple, the persistence of chromatin in vascular walls could lead to
the development of anti-DNA (and anti-histone) autoantibodies
and vasculitis. A common dermatological feature of SLE is the
butterfly erythema on the face and photosensitivity (Figure 2B).
Systemic lupus erythematosus or SLE-like disease can be caused
by multiple mechanisms. Often, SLE is related to excessive apop-
tosis and production of cellular waste or its defective clearance.
A common thought is that apoptotic cells represent a challenge
to immune tolerance. It has been demonstrated that apoptotic
keratinocytes (rendered apoptotic by ultraviolet B radiation or
viral infection) are specifically recognized by human C1q in an
antibody-independent manner (32). Furthermore, there is evi-
dence that viral and self-antigens are concentrated and clustered
in blebs of apoptotic keratinocytes (35). This has led to the sug-
gestion that C1q may be critical for proper recognition, clearance,
and processing of self-antigens contained within apoptotic surface
blebs. About 20–40% of SLE patients have autoantibodies to the
collagen-like region (CLR) of C1q (36), but many SLE patients
also have autoantibodies directed to the globular domain of C1q
(37). In some SLE patients, a low molecular weight form of C1q is
produced (38) resulting in functional C1q deficiency.
Levels of anti-C1-INH IgG antibodies have been shown to be
significantly higher in SLE patients than in controls, and to cor-
relate with the duration and activity of the disease. However, no
correlation between anti-C1-INH and anti-C1q IgG antibodies
was found (39). It has also been reported that levels of antibod-
ies directed against mannose-binding lectin (MBL) are signifi-
cantly higher in patients with SLE compared to healthy subjects.
No significant difference in the anti-MBL antibodies was found
between patients with active or inactive disease (40). Epidemio-
logical studies on SLE cohorts have not indicated MBL deficiency
as a susceptibility factor for SLE (41).
VASCULITIC SYNDROMES AND URTICARIAL VASCULITIS
Circulating C3dg and soluble terminal complement complexes
(SC5b-9) as well as perivascular deposits of C3d and MAC have
been found in skin lesions of patients with vasculitis (42). These
are all evidence for both systemic and local complement acti-
vation. MAC has been detected in the vascular walls of skin
samples from patients with Henoch–Schönlein purpura and SLE
(43, 44). In different forms of vasculitis, including leucocytoclas-
tic vasculitis, C3 with IgG is usually seen on endothelial cells
of the dermal vessels by immunofluorescence (IF) microscopy.
The kallikrein–kinin system has been reported to be activated in
vasculitis leading to the release of bradykinin. Complement acti-
vation on the endothelium leads to MAC formation, cell activation
with consequent production of chemokines, membrane blebbing,
and release of membrane microparticles. C3a and C5a induce
endothelial cytokine release and an increase in vascular leakage.
The terminal complement complex C5b-9, either in a soluble form
(SC5b-9) or as MAC, can induce increased endothelial permeabil-
ity (45, 46). Recent findings suggest that stimulation of neutrophils
by anti-neutrophil cytoplasmic antibody (ANCA) causes release
of factors that activate complement via the alternative pathway,
thus initiating an inflammatory amplification loop that mediates
the severe necrotizing inflammation of ANCA-associated vasculi-
tis (47). Thus, both the complement and the kinin systems are
thought to become activated during vasculitis and play a central
role in disease pathogenesis.
Hypocomplementemic urticarial vasculitis syndrome (HUVS)
is associated with anti-C1q antibodies and low levels of the clas-
sical pathway components, namely C1q, C2, C4, and C3. The
possible mechanisms of vascular damage include formation of
immune complexes, anti-C1q antibodies, and a T-lymphocyte
response (48). In addition, anti-C1q antibodies may interfere with
the clearance of apoptotic cells, influencing induction and expres-
sion of autoimmunity (49). HUVS presents as a clinically more
aggressive and long-standing disease (>6 months) with urticarial
burning and pruritic lesions than normocomplementemic urticar-
ial vasculitis (Figure 2C). Additionally, clinical findings such as
leucocytoclastic vasculitis, severe angioedema,pulmonary involve-
ment, arthritis, glomerulonephritis, and recurrent abdominal pain
are possible. Anti-C1q antibodies have been described also, e.g., in
SLE and Sjögren’s syndrome, and some patients with HUVS may
have clinical features of these connective tissue diseases (50).
BULLOUS SKIN DISEASES
PEMPHIGUS
Pemphigus, a group of bullous diseases affecting skin and oral
mucosa, is caused by an antibody-mediated autoimmune reaction
to desmogleins (Dsg), desmosomal transmembrane glycoproteins.
Autoantibodies have been suggested to activate the complement
system leading to loss of cohesion of individual epidermal ker-
atinocytes (acantholysis) and intraepidermal blisters. Pemphi-
gus is classified into pemphigus vulgaris (PV), with suprabasal
acantholysis, and into pemphigus foliaceus (PF) and pemphigus
erythematosus (PE), with acantholysis in the more superficial epi-
dermis. PV is characterized by IgG autoantibodies against Dsg 3,
while the target in PF and PE is Dsg 1. About 50% of patients with
PV have also Dsg 1 autoantibodies. PV patients with oral mucosal
lesions have predominantly Dsg 3 antibodies, while PF patients
with Dsg 1 do not have mucosal symptoms (51, 52). Dsg antigens
are localized in the intercellular substance (ICS) of the epider-
mis and autoantibodies to ICS are also present in patients with
pemphigus. Components of both the classical and the alterna-
tive pathway including C1q, C4, C3, and properdin (P) are found
in the ICS in PV lesions (53). It is assumed that a direct toxic
effect of MAC on epidermal cells plays a role in the pathogen-
esis because, in addition to C1q, C3, and C4, also C5, C7, and
Frontiers in Medicine | Dermatology January 2015 | Volume 2 | Article 3 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panelius and Meri Complement system in dermatological diseases
C9 and the MAC-neoantigen have been found in the ICS area
both in PV and PF (54). Complement consumption and activa-
tion products can be observed in the blister fluids. In comparison,
complement levels in the blister fluids produced on the skin of nor-
mal individuals are equivalent to those in serum, and the levels of
activation products are very low. This indicates a disease-specific
activity. IF microscopy analysis of the skin biopsies shows usually
C3 and IgG between keratinocytes. Tissue-bound and circulat-
ing IgG autoantibodies in pemphigus patients mainly belong to
IgG1 and IgG4 subclasses, of which IgG1 is a potent complement
activator (55).
BULLOUS PEMPHIGOID
Bullous pemphigoid (BP) is a generalized blistering disorder char-
acterized by pruritus and rigid, subepidermal blisters (Figure 2D).
Autoantibodies against the main BP antigen BP180 and its NC16A
domain (located in collagen XVII) are seen in this disease. The tar-
get antigen is localized to hemidesmosome, the main epidermal
structure maintaining adherence of the epidermis to the basement
membrane (56, 57). Subepidermal blistering is initiated by anti-
BP180 antibodies binding to the basement membrane zone (BMZ)
and mediated by complement activation via the classical pathway,
mast cell degranulation, and neutrophil infiltration (58, 59). Com-
plement activation and chemotactic peptides attract neutrophils
and other inflammatory cells to the site. Complement components
present in the region of blister formation include C1, C3, C3d, P,
C5, and MAC. Direct IF staining of the skin biopsy shows usually
C3 and IgG at BMZ.
A disease belonging to the pemphigoid group is linear IgA-
dermatosis, also called the chronic bullous disease of childhood.
Here, the antigen is also BP180/NC16A but direct IF of the skin
biopsy shows linear IgA fluorescence. Also IgA antibodies against
the NC16A domain of BP180 have been found (60). IgA does,
however, not activate the complement system. On mucosal mem-
branes, IgA competes with IgG and thereby can prevent comple-
ment activation. Nevertheless, aggregates of heavily glycosylated or
modified IgA, like in IgA nephropathy, could activate the alterna-
tive pathway of the complement system and contribute to disease
pathogenesis.
MUCOUS MEMBRANE PEMPHIGOID
Mucous membrane pemphigoid, also called as cicatricial pem-
phigoid (CP) is a heterogeneous disease with subepidermal blis-
tering. The main antigen in this disease is also BP180 protein but
various other autoantigens have been identified including laminin
5 (epiligrin) and α6β4 integrin. Autoantibodies against BP180 are
thus often negative in this patient group and the diagnosis is mainly
based on direct IF of the mucosal biopsy, which shows deposi-
tion of IgG, C3, and IgA at the BMZ (59). Autoantibodies in CP
mainly belong to IgG4 and IgG1 subclasses, while anti-epiligrin
CP autoantibodies against laminin 5 belong usually to the IgG4
subclass (55). Because IgG4 is not a complement-activating IgG
subclass, sera from patients with autoantibodies against laminin 5
do not fix C3 to the epidermal basement membrane and do not
induce leukocyte-dependent dermal–epidermal separation in vitro
(55). This suggests that complement activation does not play a
major role in all forms of CP.
EPIDERMOLYSIS BULLOSA ACQUISITA
A similar kind of complement activation with dermoepidermal
separation as in BP is seen also in epidermolysis bullosa acquisita
(EBA) and in pemphigoides gestationis. Complement-induced
inflammation is pronounced in EBA, where subepidermal blis-
ters develop at the sites of trauma leading to atrophic scars (22).
Circulating and tissue-bound autoantibodies directed against type
VII collagen are characteristic for EBA. Type-VII collagen forms
anchoring fibrils that connect the epidermis and the BMZ to the
papillary dermis. Autoantibodies against type-VII collagen are able
to activate the complement system in vitro and in vivo. Deposition
of various complement components, including C3b and MAC, are
commonly found in the skin of EBA patients (59).
PEMPHIGOIDES GESTATIONIS
In pemphigoides gestationis (pemphigoid of pregnancy, earlier
referred to as herpes gestationis) subepidermal blisters arise dur-
ing the second and third trimesters of pregnancy. Autoantibodies
against BP180 antigen are found also in this disease. Linear depo-
sition of C3b and, to a lesser extent, of IgG is seen at BMZ by direct
IF microscopy.
DERMATITIS HERPETIFORMIS
Dermatitis herpetiformis (DH), a celiac disease-related skin disor-
der, is characterized with itchy blistering skin lesions especially at
elbows and knees. The major antigen, as in the celiac disease, is tis-
sue (=type 2) transglutaminase (tTG) although epidermal (=type
3) transglutaminase (eTG) has been identified within the papillary
IgA granules in BMZ in DH. Direct IF microscopy shows mainly
IgA but also C3 and IgM in the small vessels of papillary dermis.
A subpapillary vascular fluorescence is also sometimes observed.
Skin IgA is colocalized with eTG in the vessel walls, which indicates
a role for anti-eTG antibodies in the pathogenesis of skin symp-
toms (61). As mentioned before, IgA does not usually activate the
complement system.
PARTIAL LIPODYSTROPHY
Partial lipodystrophy (PLD) is a rare disease characterized by a
symmetric loss of subcutaneous fat usually from the face, arms,
and trunk. It is associated with an abnormal complement activator,
the C3 nephritic factor (C3NeF), low C3 levels, and membranopro-
liferative glomerulonephritis type II (MPGN II) (62). Because of
dense intramembranous deposits of C3b and components of MAC
in glomerular basement membranes, MPGN II is nowadays called
as dense deposit disease or DDD (63). C3NeF is an IgG autoan-
tibody, which binds to and stabilizes the alternative pathway C3
convertase (C3bBb). It promotes C3 activation, causing C3 con-
sumption. The onset of the disease is usually in early childhood,
sometimes following an acute viral infection. The mechanism of
lipodystrophy is unknown, but could be related to small vessel vas-
culitis caused by C3b deposition. Adipose cells produce substantial
amounts of factor D (also known as adipsin). Thus, it is also pos-
sible that hyperactivation of the alternative pathway in the vicinity
of or targeted at fat cells could cause direct damage to them.
Partial lipodystrophy has been reported to be associated with
autoimmune disorders such as Sjögren’s syndrome, myasthenia
gravis, idiopathic thrombocytopenic purpura, Raynaud’s phe-
nomenon, scleroderma, Hashimoto’s disease, and SLE (62, 64). An
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additional autoantibody, C4 nephritic factor (C4NeF), has been
found to coexist in some patients with MPGN II and hypocom-
plementemia (65). In additon, Savage et al. (66) have reported
three patients with acquired generalized lipodystrophy, low C4
levels, and autoimmune hepatitis. The complement system is
linked to lipid metabolism by multiple ways and MAC can destroy
adipocytes, but why complement hypercatabolism causes PLD is
not fully understood.
COMPLEMENT DEFICIENCY STATES AND SKIN INFECTIONS
Pyogenic skin infections have been associated with the lack of
C2 as well as with factor I deficiency. Factor I is a fluid-phase
inactivator of C3b and C4b thus influencing both the alterna-
tive and classical pathways. The deficiency leads secondarily to C3
and factor B deficiencies. Also C8 deficiency has been associated
with chronic pyogenic infections or with xeroderma pigmentosa
(67), but apparently this is a rare association. The lack of C4A
is associated with increased likelihood of recurrent severe herpes
infections (68). Severe meningococcal infections are often linked
to immunodeficiencies. Risk of invasive neisserial infections is
increased especially in deficiencies of properdin or of the terminal
complement components (C5, C6, C7, C8, or C9) (69, 70).
The complement receptors CR1 and CR3 are expressed pre-
dominantly on leukocytes (CR1 also on erythrocytes and glomeru-
lar podocytes) and CR2 on B cells and dendritic cells. Rare patients
with a complete deficiency in CR3 have repeated infections par-
ticularly on the skin and mucosal membranes, which heal leav-
ing paper-thin scars. It is thought that CR3 deficiency leads to
leukocyte adhesion deficiency (LAD) and an inability of the CR3-
deficient neutrophils to mount a respiratory burst in response to a
phagocytic stimulus (67). The integrin β-chain (CD18) and sub-
sequently the CD11a/18, CD11b/18 (CR3), and CD11c/18 (CR4)
receptors are absent in LAD.
SKIN MANIFESTATIONS CAUSED BY MICROBES EVADING
COMPLEMENT ATTACK
BORRELIAE
Lyme borreliosis (LB) is caused by spirochetes belonging to the
Borrelia burgdorferi sensu lato group. The main causative sub-
species are B. afzelii, B. garinii, and B. burgdorferi sensu stricto,
although new subspecies B. valaisiana, B. spielmanii (71), B. lusi-
taniae, and B. bissettii (72) have also been reported in Europe.
Cutaneous symptoms include early-stage erythema migrans, lym-
phadenosis benigna cutis (lymphocytoma), and late-stage acro-
dermatitis chronica atrophicans (ACA) (73). Lymphocytoma and
ACA are predominantly caused by B. afzelii and therefore mostly
seen only in Europe. In the US and Canada, B. burgdorferi sensu
stricto is the main causative agent of LB: arthritis often preceeded
by erythema migrans.
A typical feature of Borrelia spirochetes is their ability to escape
immune clearance and survive for a long time in their human or
animal hosts. To protect themselves and to avoid attack by the
complement system, Borrelia spirochetes bind soluble comple-
ment regulatory proteins to their surfaces. There is evidence that
serum-resistant B. burgdorferi sensu stricto and B. afzelii are able to
bind complement inhibitors FH and factor H-like protein-1 (FHL-
1) (74–76) as well as the classical pathway inhibitor C4bp (77). We
have also demonstrated that all borrelial subspecies causing human
infections, including several strains of B. garinii, carry ospE genes
to protect themselves against complement attack in vivo (78). FH
and FHL-1 control C3b formation by inhibiting the formation and
activity of the AP C3 convertase enzyme, C3bBb, and by acting as
cofactors for factor I-mediated inactivation of C3b. The bind-
ing of FH to the borrelial surface occurs via two main proteins,
outer surface protein E (OspE) and CspA, also called complement
regulator-acquiring surface protein-1 (CRASP-1) (74–76, 79, 80).
Several plasmid-encoded OspE paralogs have been reported to
be responsible for FH binding to Borrelia and to mediate com-
plement resistance (81, 82). We have previously presented that
OspE interacts with the C-terminal short consensus repeats (SCRs)
19–20 of FH (75, 83). Figure 3 shows a scheme of complement
activation and inhibition on complement sensitive and resistant
bacteria.
GROUP A STREPTOCOCCUS
Group A Streptococcus (Streptococcus pyogenes) is one of the
most important human pathogens. It causes skin diseases such
as impetigo (pyogenic skin infections), erysipelas, scarlet fever,
cellulitis, and wound infections. It also acts as a trigger for skin
purpura and vasculitis or for psoriasis guttata. A more severe sep-
tic form of a skin manifestation is necrotizing fasciitis, and S.
pyogenes can also cause streptococcal toxic shock syndrome.
The major surface protein of S. pyogenes is M protein, which
is involved in the protection of the bacterium from phagocytosis.
The main immunological systems for elimination of the bacte-
ria are the complement system, antibodies, and phagocytic cells.
Because of a possible capsule and thick peptidoglycan layer on the
bacteria, MAC is not effective in directly killing of the bacteria.
Several specific ways of S. pyogenes to avoid complement attack
have been described. These include acquisition of host inhibitors
of C3- and C5-convertases (FH and C4bp), a C5a chemotaxin
cleaving enzyme (C5a peptidase) and a suggested inhibitor of
the terminal complement complexes (streptococcal inhibitor of
complement, SIC). By binding antibodies via the Fc-region, the
bacteria can also inhibit immunoglobulin-mediated complement
activation and opsonization (84–87). As the binding of comple-
ment FH is important in the pathogenesis of S. pyogenes infections,
its inhibition could provide a novel therapeutic approach (88). A
variant of FH (Y4024) that predisposes to age-related macular
degeneration protects against severe group A streptococcal infec-
tions, because the bacteria cannot bind this variant so well to their
surfaces (88).
STAPHYLOCOCCUS AUREUS
Staphylococcus aureus is a major human pathogen causing diseases
ranging from superficial skin infections and abscesses to invasive
infections such as osteomyelitis, endocarditis, and sepsis (89). This
pathogen can secrete small proteins that interfere with functions of
the complement component C3 and suppress complement activa-
tion leading to inhibition of opsonization and blocking generation
of chemotactic C3a and C5a. A key inhibitor is SCIN, the staphy-
lococcal inhibitor of the C3bBb convertase. S. aureus can also
enhance FH-mediated complement regulation on the microbial
surface. This occurs by secreting the extracellular protein Ecb,
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FIGURE 3 | Activation and inhibition of the complement system on
complement sensitive and resistant bacteria. The upper part shows the
normal situation in complement activation, where a microbe becomes a
target for complement attack. The lower part shows how borrelial OspE/CspA
(or any other similar microbial protein) binds factor H to block complement
activation on the bacterial surface. FH, factor H; B, factor B.
which promotes binding of FH to C3b to downregulate com-
plement activation (90). S. aureus can thereby use host FH and
bacterial Ecb in a concerted action to eliminate C3b at the site of
infection. S. aureus binder of IgG (Sbi) can prevent binding of
IgG to Fcγ receptors and modulate binding of C3b to FH (91).
The N-terminus of the extracellular fibrinogen binding protein
(Efb) inhibits platelet function by binding fibrinogen and its C-
terminal part binds to the C3d-domain of C3 and C3b (92, 93).
Both Sbi and Efb are also suggested to be able to form tripartite
complexes with host complement FH (91, 94). A recent study indi-
cated that Efb can block neutrophil-mediated phagocytosis of S.
aureus (95).
THERAPEUTIC POSSIBILITIES FOR COMPLEMENT-MEDIATED
DISEASES
C1 ESTERASE INHIBITOR
C1 esterase inhibitor concentrate from human plasma (BerinertR,
Cetor/CebitorR, CinryzeR) has been in clinical use for treat-
ing acute type I and II HAE since 1973. In the beginning, it
was regarded as an emergency therapy only. After the availabil-
ity of purified and virus-inactivated, C1-INH concentrates the
indication was extended stepwise to milder forms of the dis-
ease (96). C1-INH concentrates at doses of 20 U/kg provide a
fast relief of symptoms for HAE attacks (97). The treatment
effects are similar in facial and abdominal attacks, as well as
in moderate and severe attacks. Additionally, a recombinant
analog of C1-INH concentrate, alphaconestate (RuconestR), has
become available for clinical use in type I and type II HAE. In
the US, a recombinant protein kallikrein inhibitor ecallantide
(KalbitorR) has been approved for the treatment of HAE. C1-INH
concentrate has also been used with improvement in prognosis for
patients with capillary leakage syndrome following bone marrow
transplantation (98).
ICATIBANT
Icatibant (FirazyrR) is a bradykinin type 2 (B2) receptor antago-
nist. It is a synthetic decapeptide used for treating the autosomal
dominant type of HAE lacking C1-INH. It controls the effects
of increased levels of bradykinin seen in HAE. Thus, it does not
directly influence the complement levels. As an example of an off-
label indication, icatibant was used successfully in severe capillary
leakage syndrome caused by a Puumala hantavirus infection (99).
ECULIZUMAB
Eculizumab (SolirisR) is a long-acting humanized monoclonal
antibody against complement C5. It inhibits the cleavage of C5
into C5a and C5b hence blocking the generation of C5a ana-
phylatoxin and formation of MAC. This treatment was initially
registered for patients with paroxysmal nocturnal hemoglobinuria
(PNH), where an acquired defect in the glycophosphoinositol-
anchored natural complement inhibitors, CD55 and CD59 leads
to complement-mediated hemolysis (100). Recently, eculizumab
has been registered also for the use in atypical hemolytic uremic
syndrome (aHUS) and it has been used also for the treatment of
thrombotic thrombocytopenic purpura (101). Since eculizumab
practically converts the patients deficient in the terminal C path-
way, their susceptibility to meningococcal disease increases. There-
fore, appropriate prophylaxis, vaccination against Neisseria menin-
gitidis and antibiotics, is required before the therapy can be
started.
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MICROBIAL COMPLEMENT INHIBITORS AS VACCINES
Complement inhibiting surface proteins of pathogenic bacteria
have been suggested as candidates for future, function-based,
vaccines (102). An immune response against such surface pro-
tein would recognize the microbe and neutralize its complement
resistance, which is key bacterial virulence mechanism. Bacter-
ial complement inhibitors often bind the soluble inhibitors FH or
C4bp. They would act as vaccine candidates for preventing diseases
such as group B meningococcal meningitis, systemic pneumococ-
cal or group B streptococcal disease, and LB. In fact, serogroup
B meningococcal factor H binding protein (FHBP) is already
a component in a recently approved new vaccine (Bexsero®,
Novartis).
CONCLUSION
The complement system plays both protective and harmful roles in
disease. Better understanding of the complex interactions between
various components of the complement pathway and their inter-
actions with other immune pathways as well as with the coagu-
lation and kinin systems are essential for understanding various
aspects of disease pathogenesis. Characterization of the role of
the complement system in the diseases may lead to better ther-
apeutic opportunities. The availability of effective C inhibitors
for the classical pathway (C1-INH) and for the terminal path-
way (eculizumab, anti-C5) provides new opportunities to treat
life-threatening diseases like HAE, PNH, and aHUS.
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